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Clozapine impairs gastrointestinal motility owing to its anticholinergic and antiserotonergic 
properties. This commonly leads to constipation, and potentially to more severe complications such 
as bowel obstruction and ischemia. The aim of this study is to determine whether or not genetic 
variations in the genes encoding muscarinic and serotonergic receptors (CHRM2, CHRM3, HTR2, 
HTR3, HTR4, and HTR7) explain the variations in incidence of constipation and anticholinergic 
symptoms during clozapine treatment. Genes associated with opiate-induced constipation were also 
included in this analysis (TPH1, OPRM1, ABCB1, and COMT).  
Procedures 
Blood samples from 176 clozapine-treated, Finnish, Caucasian patients with schizophrenia were 
genotyped. Constipation and anticholinergic symptoms were rated using the Liverpool University 
Neuroleptic Side Effect Rating Scale self-report questionnaire. In total, 192 single-nucleotide 
polymorphisms (SNPs) were detected, and grouped to formulate a weighted genetic-risk score (GRS).  
Results 
No significant associations between individual SNPs or GRSs and constipation or laxative use were 
observed. A GRS of 19 SNPs in CHRM2, CHRM3, HTR3C, HTR7, ABCB1, OPRM1 and TPH1 was 
associated with anticholinergic symptoms in a generalized linear univariate (GLM) model with body-
mass index, clozapine monotherapy and GRS as explaining variables (permuted p = 0.014). GLM 
analysis performed on the opiate-induced constipation associated SNPs and a single CHRM3 SNP 
revealed an association between anticholinergic symptoms and a score of 8 SNPs (adjusted p = 0.038, 
permuted p = 0.002).  
Conclusions 
Two GRSs are able to predict the risk of anticholinergic symptoms in patients receiving clozapine, 
and possibly an increased risk of gastrointestinal hypomotility.  




Constipation is a common adverse effect of clozapine that is reported to occur in 14–60% of patients 
receiving treatment with this drug (1, 2), often leading to increased use of laxative medication (3). 
The impairment of gastrointestinal motility associated with clozapine can also result in severe 
complications such as dysphagia, ileus, intestinal obstruction, bowel ischemia, and megacolon. 
Among clinicians, these risks seem to be less well known than clozapine-induced agranulocytosis, 
despite clozapine-induced gastrointestinal hypomotility and agranulosytosis having similar 
prevalences (4.0–8.0 ‰ versus 3.8–8.0 ‰). Furthermore, clozapine-induced gastrointestinal 
hypomotility is associated with a greater risk of mortality, and careful monitoring of patients 
receiving clozapine for symptoms of gastrointestinal hypomotility is recommended. (4, 5)  
 
Clozapine-induced constipation seems to be associated with the anticholinergic and antiserotonergic 
properties of this agent (5, 6). In the absence of clozapine, acetylcholine stimulates muscarinic 
receptors in both smooth muscle cells and the interstitial cells of Cajal (ICC) of the gastrointestinal 
tract, the latter of which function as the pacemaker cells of the gastrointestinal tract (7). Muscarinic 
receptors (of the M2 and M3 subtypes) are expressed in ICCs and smooth muscle cells of the 
gastrointestinal tract (8). However, other anticholinergic agents with an efficacy similar to that of 
clozapine have much lower risks of gastrointestinal hypomotility. For example, the risk of 
constipation associated with use of clozapine is three times greater than that associated with 
chlorpromazine (9). Treatment with clozapine is also associated with a higher risk of ileus than that 
of other antipsychotics, as demonstrated by data from a large European study (10). This increase in 
risk is proposed to be caused by the antiserotonergic effects of clozapine (5). Clozapine is an 
antagonist of several 5-hydroxytryptamine receptors (5-HT2, 5-HT3, 5-HT6, and 5-HT7) (11). 
Serotonin also has a complex and crucial but still controversial role in gut function. Data from many 
studies have suggested that 5-HT receptors, especially 5-HT3 and 5-HT4, have an important role in 
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the regulation of gut motility. (5, 12). 5-HT2 receptors have been suggested to modulate visceral 
sensation and 5-HT7 receptors might be involved in mediating relaxation of gastrointestinal smooth 
muscle. Furthermore, inhibition of 5-HT3 receptors has been reported reduce the rate of colon transit, 
inhibit gastrocolic reflexes, increase the level of colonic compliance and possibly reduce intestinal 
sensitivity to distension. (5) 
 
The aim of this study is to determine the influence of genetic variations in different subtypes of 
muscarinic and serotonergic receptors, and whether such variations can explain the variable incidence 
of constipation or anticholinergic symptoms during clozapine treatment. Interactions between such 
variations and the risk of constipation or anticholinergic symptoms caused by antipsychotic 
medications have not been studied previously. All muscarinic and serotonergic subtypes that have 
been previously suggested to have a role in regulating gut motility were included in this study. Single-
nucleotide polymorphisms (SNPs) in the genes encoding the M2 and M3 muscarinic receptors 
(CHRM2, CHRM3) and the 5-HT2, 5-HT3, 5-HT4 and 5-HT7 receptors (HTR2, HTR3, HTR4, and 
HTR7) were extracted. Additional analyses were performed, including SNPs in TPH1, OPRM1, 
ABCB1, CHRM3 and COMT, which have all previously been suggested to contribute to the variability 
in incidence of constipation among patients with cancer receiving treatment with opioids (13).  TPH1 
encodes tryptophan 5-hydroxylase 1, which catalyzes the first and rate-limiting step in the 
biosynthesis of serotonin (14). TPH1 transcript levels are increased in patients with chronic 
constipation (15). OPRM1 encodes the mu-type opioid receptor. ABCB1 encodes Multidrug 
resistance protein 1, a protein that transports various molecules across extracellular and intracellular 
membranes. Furthermore, ABCB1 is widely expressed in various tissues, including the bowel, blood-
brain barrier, liver and kidneys (16). COMT encodes catechol O-methyltransferase, an enzyme that 




Materials and Methods 
 
Patients 
The sample was screened from 256 patients, of which 19 declined to participate in this study. Samples 
were collected from three hospital districts in western Finland (Satakunta, Pirkanmaa, and Seinäjoki). 
Inclusion criteria included a current F2-group diagnosis, according to the International Classification 
of Diseases, Tenth Revision (ICD-10), and a stabilized clozapine treatment. Patients with organic 
brain diseases were excluded from the analysis. The study population comprised 237 patients 
receiving clozapine (136 men, 101 women, with a mean age 42.5 ± 11.0 years) who were diagnosed 
with either schizophrenia (n = 223, 94.1%), schizoaffective disorder or delusional disorder. The mean 
elapsed time from first hospitalization owing to a psychotic episode was 17.3 years (± 10.0 years). 
All patients were adults (≥18 years of age), Caucasian and of Finnish origin. Blood samples were 
obtained from 190 patients, of which 176 genotyped patients were eligible to remain in the study after 
quality controls. Patients gave written, informed consent prior to participation. The study was 
approved by the Ethics Committee of Satakunta Hospital District on the 23rd of April 2008 and was 
conducted in accordance with the Tenets of the Declaration of Helsinki. More detailed information 
on the data collection process and the clinical and demographic characteristics of the study population 
is provided in our previous studies (17, 18). 
 
Of the 176 patients whose samples were genotyped, 57 (32.4 %) were receiving a combination of at 
least two antipsychotics, including clozapine, and 119 patients (67.6%) were receiving clozapine 
monotherapy. All doses of antipsychotic medication were converted to chlorpromazine equivalents 
(19). The mean daily dose of clozapine received was 403 mg (SD ± 152 mg) or 806 mg (SD ± 304 
mg) expressed as a chlorpromazine equivalent dose. The mean total antipsychotic dose received was 
912 mg (SD ± 304 mg) as a chlorpromazine equivalent dose. More than half of all patients had 
received clozapine treatment for >5 years and none for <3 months at the time of study enrollment. 
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The demographics of the genotyped patients are presented in Table 1. Eleven patients were also 
receiving anticholinergic medications, of which five were for the control of extrapyramidal symptoms 
(biperiden or similar) and six were for bladder functional disorders (oxybutynin, or trospium 
chloride).    
 
Patients completed the Liverpool University Neuroleptic Side Effect Rating Scale (LUNSERS) (20), 
a self-assessment questionnaire that consists of a list of 51 symptoms. Patients were asked to rate the 
severity of each listed adverse effect on a scale from 0 to 4 (0 = not at all, 1 = very little, 2 = a little, 
3 = quite a lot and 4 = very much). Question number 10 “constipation” was used as a dichotomized 
variable with two groups: those with no constipation at all (LUNSERS scale 0, n = 49) versus those 
who reported very little to very much constipation (LUNSERS scale 1–4, n = 127). A more-specific 
dichotomized variable was also used as a response variable, which included groups of patients who 
reported having quite a lot, to very much constipation (LUNSERS scale 3–4) or were using laxative 
medications (n = 95) versus those who reported having no constipation at all to a little constipation 
and were not receiving laxative medications (n = 81). To study patients’ anticholinergic symptoms, 
a factor was formed by summing the severity of the following five items from LUNSERS: “Dry 
mouth”, “Constipation”, “Palpitations”, “Difficulty of passing water” and “Blurred vision”. 
 
DNA extraction and genotyping 
Genomic DNA was extracted from peripheral blood leukocytes using an QIAamp DNA Blood 
Midikit and an automated biorobot M48 extraction (Qiagen, Hilden, Germany). Samples were 
genotyped using an Illumina Infinium HumanCoreExome-12 DNA Analysis Beadchip, version 1.0., 
according to the manufacturer’s instructions at Helmholtz Zentrum, München, Germany. The 
following quality control filters were applied: GenCall score <0.15, GenTrain score <0.20, sample 
and an SNP call rate <0.95, Hardy–Weinberg equation p-value <10−6, excess heterozygosity, cryptic 
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relatedness (pi-hat >0.2), gender check and multidimensional scaling (MDS). After quality control, 
176 samples and 531,983 SNPs were available, of which 192 SNPs were in the genes of interest 
(CHRM2, CHRM3, HTR2, HTR3, HTR4, HTR7, TPH1, OPRM1, ABCB1 and COMT). SNPs with a 
minor allele frequency (MAF) of <0.01 were excluded from the study. 
 
Statistical methods 
Values for comparisons between each group are presented as mean ± standard deviation of the mean, 
unless otherwise stated. Pearson correlations, chi-squared tests and t-tests were used in exploratory 
analyses of the relationships between constipation, use of laxatives and anticholinergic factor, and 
potential explanatory variables such as use of clozapine dose, clozapine and its metabolite 
norclozapine (N-desmethylclozapine) concentrations, body-mass index (BMI), smoking status, age, 
and use of benzodiazepines or selective-serotonin reuptake inhibitors (SSRIs). Reliability analysis 
for anticholinergic factor was performed using a principal components analysis for ordinal data, using 
a one-component solution in which all five items were loaded (>0.5). The Cronbach’s alpha value 
was 0.60. Generalized linear univariate models (GLMs) were used to analyze the explanatory factors: 
SNPs encoded separately with additive, dominant and recessive coding and covariates for response 
variables. The response variables analyzed with GLM were dichotomized constipation (binominal 
distribution), dichotomized constipation taking laxative use into account (binominal distribution) and 
the anticholinergic factor (Gaussian distribution). Covariates in the models were chosen primarily 
according to literature and secondarily according to the results of exploratory bivariate analyses. 
Finally, the best fitting model was used. In the GLM analysis, the SNPs were analyzed by entering 
them into the model one at a time. To adjust significance levels for multiple testing, the false-
discovery rate (FDR) was used. This accounts for the number of SNPs and different modes of 
inheritance in the GLM. SNPs were coded with additive, dominant and recessive models. Details of 
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the coding are described in our previous study (18). The statistical significance level was set at p 
<0.05. 
 
Statistical analyses were performed using R statistical analysis software (version 3.1.2, 2014, The R 
Foundation for Statistical Computing), SPSS (version 22, IBM inc.), gPLINK (version 2.050), 
PLINK (version 1.07) and Haploview analysis software (version 4.2).  
 
Genetic risk score (GRS) 
Genetic risk scores (GRSs) were calculated for each patient as a weighted sum of the risk alleles in 
relation to the studied phenotype. SNPs that had an unadjusted level of statistical significance (p 
<0.05) in the GLM models were selected for further analysis. These SNPs were inserted into the same 
model with the other coefficients and a stepwise analysis was performed using Akaike information 
criteria (AIC) (21). AIC is a method of model-based genetic mapping (22). Data obtained using AIC 
is used to identify the influential tag SNPs of the SNPs preselected with GLM by also taking into 
account the extent of linkage disequilibrium (LD) between the SNPs. SNPs that remained significant, 
as indicated by AIC, were used in the GRS. The model returned by AIC was analyzed with stepwise 
variance inflation factor (VIF) to examine collinearity between the SNPs in the GRS. The 
corresponding beta estimate value (β) from the GLM for each SNP was used to adjust the weighting 
of individual effects. The formed GRS was then used as an explanatory variable in the final GLM, 
together with other explanatory variables.  
 
Permutation test 
Linear combinations of genetic effects estimated using GLMs might overfit data and cause inflated 
type I errors. An estimation of the null distribution of the GRS test statistics is required to validate 
the GRS results (23). A permutation test was performed, in which the patient identification numbers 
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from the phenotype data were sampled. This resulted in SNP genotypes that were independent of the 
studied phenotypes. The permutation was conducted 999 times using the same statistical methods as 
described above, but with sampled data. P-values were collected for GRSs from each model in each 
sampled dataset. The result was considered statistically significant if the p-value derived from the 





In exploratory analyses, patients in the group who had more severe constipation or used laxatives 
were significantly older than those who had less-severe constipation and required no laxatives ( 41.34 
± 10.6 years of age versus 44.52 ± 11.6 years of age, t-test p = 0.035). No statistically significant 
associations were observed using analyses of the correlations between dichotomized constipation or 
anticholinergic factor and age, BMI, smoking status, gender, clozapine dose, or clozapine and 
norclozapine concentrations. Use of laxatives was associated with BMI (30.4 ± 6.1 kg/m2 versus. 
28.2 ± 6.3 kg/m2, t-test p = 0.032), with patients with a lower BMI more likely to be using laxatives. 
Use of laxatives was also associated with use of benzodiazepines (chi-square, p = 0.020), with patients 
with benzodiazepine medication also more likely to be using laxatives. Anticholinergic factor was 
also associated with use of benzodiazepines (4.45 ± 3.40 versus 5.38 ± 3.36, t-test p = 0.042) and 
with use of SSRIs (4.59 ± 3.49 versus 5.70 ± 3.13, t-test p = 0.015). No correlation between 
anticholinergic medication use and anticholinergic factor was observed (r = 0.063). Dichotomized 
constipation was not associated with use of benzodiazepines or SSRIs.  
 
In the GLM analyses, with constipation or use of laxative as the dependent variable, SNPs in CHRM2, 
CHRM3, HTR2, HTR3, HTR4 and HTR7 with, or without the inclusion of additional SNPs in TPH1, 
OPRM1, ABCB1 and COMT, no statistically significant associations were observed level in any 
model with varying combinations of additional explaining variables (age, BMI, gender, use of 
benzodiazepines or SSRIs). With anticholinergic factor as the dependent variable and BMI and SNPs 
as the explaining variables, following analysis SNPs in CHRM2, CHRM3, HTR2, HTR3, HTR4, and 
HTR7, only rs685548 remained statistically significant after FDR-adjustment (dominant coding p = 
0.038, additive coding p = 0.044). However, this association became statistically insignificant 
following FDR-adjustment when SNPs associated with opiate-induced constipation were added to 




In the GRS analysis, no significant associations between GRS and constipation or use of laxatives 
were observed. When only SNPs in CHRM2, CHRM3, HTR2, HTR3, HTR4 and HTR7 were analyzed, 
associations between the formed GRS and the anticholinergic factor remained statistically 
insignificant after permutation. When SNPs in genes associated with opiate-induced constipation 
(ABCB1, OPRM1, TPH1 and COMT) were added to the analysis, a score of 19 SNPs in CHRM2, 
CHRM3, HTR3C, HTR7, ABCB1, OPRM1 and TPH1 (table 2) was found to be associated with 
anticholinergic factor in a GLM model with BMI and GRS as explaining variables (p = 0.017). GLM 
analysis performed only on SNPs associated with opiate-induced constipation and a single SNP in 
CHRM3 that was associated with anticholinergic factor resulted in a score of 7 SNPs (p = 0.0023, 
table 2). In both models, no significant collinearity was observed between the SNPs or other predictor 











To the best of our knowledge, no previous study has examined the association between clozapine-
induced gastric hypomotility or anticholinergic symptoms related to antipsychotic medication and 
genetic polymorphisms. The main findings of this study are the two GRS (table 2) and one single 
SNP in CHRM3 (rs685548) that are associated with anticholinergic symptoms in patients with 
schizophrenia who are receiving clozapine. This effect is a result of SNPs in various genes, including 
genes linked with cholinergic (CHRM2 and CHRM3) and serotonergic neurotransmission (HTR3C, 
HTR7, and TPH1), but also with genes associated with opiate-induced constipation (ABCB1 and 
OPRM1). This finding might reflect individual genetic variations in response to clozapine or in the 
functionality of the autonomic nervous system. No statistically significant associations between SNPs 
in serotonergic or muscarinic receptors, or SNPs in genes related to opiate-induced constipation and 
constipation or laxative use were observed in this study.   
 
The model with the 19-SNP-score, BMI and clozapine monotherapy explained 43% of the variability 
in anticholinergic symptoms in clozapine-treated patients. The effect was confirmed using a 
permutation test (p = 0.014), but the high adjusted R2 value and very low p-value in the GLM (<2 x 
10-16) might contain a type I error owing to overfitting in the GRS analysis. The rs685548 SNP located 
in CHRM3 is an intron variant with a MAF of 0.36, with no other SNPs with a level of LD >0.8 r2 
present in this cohort (Table 3). No significant associations between any phenotype and CHRM3 
rs685548 have been reported previously. Furthermore, no items were found in the PubMed database 
describing any of the SNPs included in the GRSs or SNPs with a level of LD >0.8 r2. SNPs in ABCB1 
have been widely investigated. SNPs in this gene have been studied in relation to patient’s responses 
to clozapine and plasma clozapine levels (24, 25), but not in relation to anticholinergic symptoms. 
The current study cannot propose a single mechanism explaining the increased risk of anticholinergic 
symptoms during clozapine treatment, but rather suggests that the genetic effect is cumulative, owing 
to alterations in muscarinic and serotonergic receptor function (in CHRM2, CHRM3, HTR3C, and 
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HTR7), the serotonin-related enzyme TPH1, and in ABCB1 and OPRM1 function.  rs1045642 in 
ABCB1, which was also included in the GRS, might affect the absorption of clozapine from the gut, 
as previously reported (24), however, in this study, no significant association between serum 
clozapine and norclozapine concentration and anticholinergic symptoms was observed. The 
variability in anticholinergic symptoms might also be related to the functions of ABCB1 in other 
tissues. Important functional roles of ABCB1 also has an important function maintaining the blood-
brain barrier and blood-cerebral spinal fluid barrier (16). 
 
As Palmer et al. (2008) state clozapine induced gastric hypomotility is underrecognized and 
potentially life-threatening adverse effect of clozapine treatment (5). Objective evidence of 
gastrointestinal hypomotility in clozapine-treated patients has been shown by using a colonic transit 
test (26). Recent study reported that median colonic transit times are over four times longer than those 
on other antipsychotics or healthy controls and four fifths of patients using clozapine had colonic 
hypomotility (27). Furthermore, older age, female sex, treatment with clozapine, tricyclic 
antidepressants, anticholinergics and opioids are reported to be associated with an increased risk of 
ileus (28). Patients with a greater incidence of anticholinergic symptoms could have an elevated risk 
of gastric hypomotility and/or bowel complications such as ileus. Thus, the GRSs reported in this 
study could also be used as markers for the risk of these symptoms. The genes investigated in this 
study were originally selected based upon the hypothesized pharmacological effects of clozapine on 
the muscarinic and serotonergic receptors that regulate gut motility.  
 
Many confounding factors could not be taken into account by this study, such as variations in diet or 
amount of exercise, although these can both be expected to influence BMI. In this study cohort, age 
and gender were both correlated with BMI, which highlights the importance of including BMI in the 
models used. A total of 192 SNPs were selected for analysis. The ability to detect small or moderate 
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effects associated with these SNPs is limited by the relatively small sample size of the study cohort; 
however, the well-defined hypothesis and focus only on specific genes reduces the need for a larger 
sample. A similar statistical approach was used in three of our earlier reports, which included the 
same patient sample (18, 29, 30). Limitations of this study include the reliance upon self-assessment 
of the severity of constipation and anticholinergic symptoms by each patient using the LUNSERS 
questionnaire. No information on patients’ bowel movement frequencies or stool consistencies, with 
the help of stool charts, for example, was available. LUNSERS is, nevertheless, a reliable and 
validated method of measuring the adverse effects of antipsychotic treatments (31). Another 
limitation is that anticholinergic factor, as used to examine the severity of anticholinergic symptoms 
is a sum variable with only a moderate level of internal consistency (Cronbach’s alpha = 0.6). 
However, the symptoms included in the anticholinergic factor (dry mouth, constipation, palpitations, 
difficulty of passing water and blurred vision) are all commonly recognized anticholinergic symptoms 
(32). 
 
In conclusion, this study suggests that the risk of anticholinergic symptoms during clozapine 
treatment is associated with a GRS consisting of SNPs in CHRM2, CHRM3, HTR3C, HTR7, TPH1, 
ABCB1 and OPRM1 genes, in addition to rs685548 in CHRM3. No significant associations between 
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Table 1. Demographics of the genotyped patients (n = 176) 
Age mean (sd) years 43.5 (10.9) 
Gender n (%)  
 Men 
Women 
104 (59.1 %)  
72 (40.9 %) 
BMI mean (sd) kg/m2 29.8 (6.38) 
Clozapine treatment duration n (%)  
 3 months to 1 year 
1 to 5 years 
Over 5 years 
Unknown 
4 (2.3 %) 
51 (29.0 %)  
106 (60.2 %) 
15 (8.5%) 
Sum of clozapine and norclozapine 
concentrations, mean (sd) µmol/l 
 
2.40 (1.28)  




85 (48.3 %)  
89 (50.6 %) 
2 (1.1 %) 
Laxative in use n (%) 46 (26.1 %) 
Quite a lot or very much constipation or 
laxative in use n (%) 
 





Table 2. Results (test score, beta coefficients, significance levels and permutation rankings) of two general linear models with genetic risk scores, 
consisting of listed SNPs, explaining the risks of anticholinergic adverse effects summarized as ‘anticholinergic factor’, including BMI and 
clozapine monotherapy as confounding factors. 
 
* ADD = additive coding, ** DOM = dominant coding, *** REC = recessive coding 
Genes selected 
for GRS analysis 
Formed GRS BMI Clozapine monotherapy GRS    Adjusted R2 Permutation 
ranking 
  t β p t β p t β p   
CHRM2   









CHRM2 ADD rs10228048* 
CHRM2 DOM rs12535371** 
CHRM3 DOM rs685548 
CHRM3 REC rs11577797*** 
CHRM3 ADD rs6691263 
CHRM3 REC rs10925910 
CHRM3 DOM rs2841037 
HTR4 REC rs7723153 
HTR7 DOM rs7074715 
HTR7 ADD rs7074715 
ABCB1 ADD rs10276036 
ABCB1 REC rs2235023 
ABCB1 REC rs9282564 
ABCB1 DOM rs10260862 
ABCB1 DOM rs10248420 
ABCB1 ADD rs2032582 
ABCB1 ADD rs3789243 
OPRM1 REC rs2272381 
TPH1 ADD rs10832876 
3.3 0.20 
 
0.00045 -3.9 -1.7 0.00015 10.1 
 
0.65 < 2x10-16 0,43 14th out of 1 000 
permutations  








CHRM3 ADD rs685548  
OPRM1 REC rs2272381  
OPRM1 REC rs34427887 
ABCB1 ADD rs1002204  
ABCB1 ADD rs10260862 
ABCB1 REC rs2235023 
ABCB1 REC rs9282564 
TPH1 DOM rs10832876 
1.9  0.067 0.056 -3.8 -1.8 0.00018 8.6  0.79 6.1x10-15 0,36 2nd out of 1 000 
permutations  
(p = 0.002) 
22 
 
Table 3. SNPs in the two GRSs explaining anticholinergic symptoms, including SNPs with a level of LD >0.8 R2, annotations of the SNPs and 
the number of items referring to these SNPs in the PubMed database. 
 
 
 Gene SNP SNPs in > 0.8 LD (r
2) Annotation Number of citations 
of the SNP in Pubmed 
CHRM2 rs10228048  - intron - 
 rs12535371   intron, LOC349160 (ncRNA) - 
  rs1364405 (0.83)  intron - 
CHRM3 rs685548  intron - 
  rs497576 (0.80) intron - 
 rs11577797  intron - 
  rs6678395 (0.98) intron - 
 rs6691263  intron - 
  rs12090480 (0.86) intron - 
 rs10925910  - intron - 
 rs2841037  intron - 
  rs626694 (1)  intron - 
HTR4 rs7723153  intron - 
HTR7 rs7074715  - intron - 
ABCB1 rs10276036  - intron 10  
 rs2235023  - intron 3  
 rs9282564  - missense, frameshift 22  
 rs10260862 - intron 2  
 rs10248420 - intron 9  
 rs2032582 - missense 237 
 rs3789243 - intron 27 
 rs1002204  intron 1 
  rs1045642 (0.91)  cds-synon 365 
OPRM1 rs2272381  - intron 2 
 rs34427887  - STOP-GAIN - 
TPH1 rs10832876  intron - 
  rs7943884 (0.85) < 5000 base pairs before gene 
reading region, no annotation 
- 
